379 related articles for article (PubMed ID: 16793621)
21. [Evaluation of tumor markers in the management of small cell lung cancer].
Ariyoshi Y
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
[TBL] [Abstract][Full Text] [Related]
22. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
23. Differences in initial NSE levels in malignant and benign diseases of the thoracic wall.
Franjević A; Pavićević R; Bubanović G
Clin Lab; 2012; 58(3-4):245-52. PubMed ID: 22582497
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
[TBL] [Abstract][Full Text] [Related]
25. [Serum NSE (neuron-specific enolase) levels in small cell lung cancer, with special reference to the measurement of serial serum NSE levels].
Kawachi S; Shimabukuro Z; Aoyama A; Yano T; Hasegawa K; Tsuboi E; Niitani H
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2469-74. PubMed ID: 3039919
[TBL] [Abstract][Full Text] [Related]
26. Methodological and clinical evaluation of two automated enzymatic immunoassays as compared with a radioimmunoassay for neuron-specific enolase.
Schmitt UM; Stieber P; Hasholzner U; Pahl H; Hofmann K; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1996 Aug; 34(8):679-82. PubMed ID: 8877347
[TBL] [Abstract][Full Text] [Related]
27. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
28. [Neuron-specific enolase as a tumor marker in small cell bronchial carcinoma].
Gasser RW; Herold M; Müller-Holzner E; Müller LC; Salzer GM; Huber H
Dtsch Med Wochenschr; 1988 Nov; 113(44):1708-13. PubMed ID: 2846253
[TBL] [Abstract][Full Text] [Related]
29. [The prognostic value of serum neuron specific enolase detection in small cell lung cancer].
Jin B; Zhao L; Zhou C
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Dec; 24(12):722-4. PubMed ID: 11930699
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of the measurement of serum neuron-specific enolase levels in patients with lung cancer].
Yumoto Y; Shiota T; Tamai M; Okabe K; Kiura K; Shimoe T; Fujii M
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2089-93. PubMed ID: 3013098
[TBL] [Abstract][Full Text] [Related]
31. High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: diagnostic value, relation to serum neuron specific enolase, and staging.
Dowlati A; Bury T; Corhay JL; Weber T; Mendes P; Radermecker M
Cancer; 1996 May; 77(10):2039-43. PubMed ID: 8640667
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
33. [Serum neuron specific enolase (NSE) levels in patients with non small cell lung cancer].
Shibayama T; Ohnoshi T; Ueoka H; Horiguchi T; Kodani T; Segawa Y; Maeda T; Miyatake K; Takigawa N; Kimura I
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jun; 30(6):1097-102. PubMed ID: 1324376
[TBL] [Abstract][Full Text] [Related]
34. [Clinical evaluation of serum NSE and CEA in primary lung cancer patients].
Fukasawa T; Fujisawa T; Yamaguchi Y; Sasaki K; Shiba M; Yusa T; Sakio H; Momiki S; Ogawa T
Gan To Kagaku Ryoho; 1986 May; 13(5):1862-7. PubMed ID: 3010884
[TBL] [Abstract][Full Text] [Related]
35. Telomerase activity in endoscopically visible lung cancer.
Hirashima T; Yoshitaka O; Nitta T; Sasada S; Kobayashi M; Masuda N; Matsui K; Nakagawa K; Yasumitsu T; Takada Y; Kikui M; Kawase I
Anticancer Res; 2001; 21(5):3685-9. PubMed ID: 11848543
[TBL] [Abstract][Full Text] [Related]
36. [Determining the level of the tumor marker--neuron-specific enolase in patients with neoplastic and non-neoplastic diseases].
Romanova LF; Khaĭlenko VA; Kuznetsova LF; Davydov MI; Komov DV; Kulish VL; Platinskiĭ LV; Poddubskaia EV
Klin Med (Mosk); 1991 Sep; 69(9):38-9. PubMed ID: 1803146
[TBL] [Abstract][Full Text] [Related]
37. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
38. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer.
Nitta T; Fukuoka M; Masuda N; Kusunoki Y; Matsui K; Kudoh S; Hirashima T; Yana T; Ito K; Takada M
Jpn J Clin Oncol; 1995 Oct; 25(5):179-83. PubMed ID: 7474404
[TBL] [Abstract][Full Text] [Related]
39. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
40. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]